Years of researches have demonstrated that the imbalance of Th17 and Tregs contribute to the thyroid auto-immunity and the severity of autoimmune thyroid disease (AITD). The underlying mechanism comprises inherent genetic predisposition, abnormality of Th17 and Treg related biological molecules, and gut microbiota disorder. New therapeutic strategies have been developed to improve the Th17/Treg equilibrium, including regulation of intracellular signaling pathways, neutralization of Th17-related cytokines, as well as manipulation of Th17 and Treg specific transcription factors. Although a few of these agents are applied into AITD, the clinic prospect is promising.
基金：
National Natural Science Foundation of China [81100581]; China International Medical Foundation (CIMF)-Novo Nordisk China diabetes Yingcai Funding; CIMF-Novo Nordisk China beta Academy Funding [20110059]; Fundamental Research Funds for the Central Universities [0118540208]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|3 区医学
小类|3 区医学：研究与实验3 区药学
最新[2025]版：
大类|3 区医学
小类|2 区药学3 区医学：研究与实验
JCR分区：
出版当年[2016]版：
Q2MEDICINE, RESEARCH & EXPERIMENTALQ2PHARMACOLOGY & PHARMACY
最新[2023]版：
Q1MEDICINE, RESEARCH & EXPERIMENTALQ1PHARMACOLOGY & PHARMACY
